Cancer Associated Microangiopathic Hemolytic Anemia: A Rare Paraneoplastic Syndrome

Authors

  • Aravind Reddy Kuchkuntla Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL Author
  • Sumiaya Khaja Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL Author
  • Nitish Singh Nandu Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL Author
  • Swetha Paduri Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL Author
  • Hafzah Husam Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL Author
  • Shreya Desai Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL Author
  • Sangeetha Mehendale Department of Pathology, St. Mary’s Nazareth Hospital, Chicago, IL Author
  • Brendon Gilmore Department of Hematology and Oncology, St. Mary’s Nazareth Hospital, Chicago, IL Author
  • Palak Desai Department of Hematology and Oncology, St. Mary’s Nazareth Hospital, Chicago, IL Author

DOI:

https://doi.org/10.47363/JONRR/2021(2)137

Keywords:

Cancer, Paraneoplastic Syndrome, Hemolytic Anemia

Abstract

Microangiopathic hemolytic anemias (MAHA) are secondary to damage of RBCs because of endothelial vascular damage of blood vessels leading to hemolysis. MAHAs are characterized by negative coombs test and are associated with several etiologies that include can be either hereditary complement or ADAMTS13 deficiency or sepsis or malignancy. Cancer associated MAHA (CA-MAHA) is a rare and is seen in patients with advanced metastatic disease. CA-MAHA has significant mortality rate and chemotherapy is the only therapeutic option, however overall survival is poor. Here we, present a rare case of CA-MAHA secondary to metastatic signet ring cell carcinoma with an unknown primary. In patients, when the cause of progressive MAHA is unknown, the possibility of cancer associated MAHA must be considered and a comprehensive work up for an underlying malignancy must be done.

Author Biographies

  • Aravind Reddy Kuchkuntla, Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

    Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

  • Sumiaya Khaja, Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

    Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

  • Nitish Singh Nandu, Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

    Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

  • Swetha Paduri, Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

    Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

  • Hafzah Husam, Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

    Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

  • Shreya Desai, Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL

    Department of Internal Medicine, Rosalind Franklin University of Medicine, North Chicago, IL 

  • Sangeetha Mehendale, Department of Pathology, St. Mary’s Nazareth Hospital, Chicago, IL

    Department of Pathology, St. Mary’s Nazareth Hospital, Chicago, IL

  • Brendon Gilmore, Department of Hematology and Oncology, St. Mary’s Nazareth Hospital, Chicago, IL

    Department of Hematology and Oncology, St. Mary’s Nazareth Hospital, Chicago, IL

  • Palak Desai, Department of Hematology and Oncology, St. Mary’s Nazareth Hospital, Chicago, IL

    Department of Hematology and Oncology, St. Mary’s Nazareth Hospital, Chicago, IL

Downloads

Published

2021-06-10

Issue

Vol. 2 No. 3 (2021): Volume 2 Issue 3

Section

Articles